J Ahuixotl Gutiérrez-Aceves, Felipe Alexis Avalos-Salgado, Jorge Ivan Gamez-Nava, Laura Gonzalez-Lopez, Sergio Antonio González-Vázquez, Reynaldo Arellano-Cervantes, Mario Alberto Mireles-Ramírez, Jazmin Marquez-Pedroza, Melissa Ramirez-Villafaña, Eli Efrain Gomez-Ramirez, Fabiola Gonzalez-Ponce, Ana Miriam Saldaña-Cruz, Norma Alejandra Rodriguez-Jimenez, Ernesto German Cardona-Muñoz, Sylvia Totsuka-Sutto, Juan Manuel Ponce-Guarneros
Urinary tract infections (UTIs) constitute one of the main complications in kidney recipients, increasing both morbidity and mortality. Due to the resurgence of antimicrobial resistance, new prophylactic approaches are being investigated. Nitrofurantoin is an antibiotic from the nitrofuran group that is effective against several Gram-negative and Gram-positive organisms; hence, there has been a resurgence in its prescription for treating MDR pathogens. Objectives : This study aims to assess the effectiveness of nitrofurantoin as an add-on to conventional therapy (amikacin + ceftriaxone or cefotaxime) for the treatment of urinary tract infections in kidney recipients...
September 3, 2024: Journal of Clinical Medicine